We are live on
!
Find out more
GFM
GF Fund Management Portfolio holdings
AUM
$5.98B
1-Year Est. Return
80.99%
This Fund
S&P 500
This Quarter
Est. Return
+7.58%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.56B
Cap. Flow
% of AUM
98.7%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$400M |
| 2 |
Apple
AAPL
|
+$352M |
| 3 |
Microsoft
MSFT
|
+$326M |
| 4 |
Amazon
AMZN
|
+$218M |
| 5 |
Meta Platforms (Facebook)
META
|
+$195M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.41% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Atea Pharmaceuticals
AVIR
$379M
| $5.94K | ﹤0.01% |
+1,773
| New | +$5.89K |
|
|
ITOS
602
DELISTED
iTeos Therapeutics
ITOS
| $5.89K | ﹤0.01% |
+767
| New | +$6.59K |
|
603
Vanda Pharmaceuticals
VNDA
$312M
| $5.86K | ﹤0.01% |
+1,224
| New | +$5.88K |
|
604
AC Immune
ACIU
$241M
| $5.61K | ﹤0.01% |
+2,077
| New | +$6.49K |
|
605
Entergy
ETR
$50.4B
| $5.54K | ﹤0.01% |
+73
| New | +$5.27K |
|
606
Foghorn Therapeutics
FHTX
$278M
| $5.51K | ﹤0.01% |
+1,167
| New | +$8.5K |
|
607
Amylyx Pharmaceuticals
AMLX
$2.31B
| $5.44K | ﹤0.01% |
+1,439
| New | +$6.77K |
|
608
4D Molecular Therapeutics
FDMT
$526M
| $5.41K | ﹤0.01% |
+971
| New | +$7.62K |
|
609
C4 Therapeutics
CCCC
$405M
| $5.33K | ﹤0.01% |
+1,482
| New | +$7.37K |
|
610
Larimar Therapeutics
LRMR
$398M
| $5.19K | ﹤0.01% |
+1,340
| New | +$8.85K |
|
|
ARTV
611
Artiva Biotherapeutics
ARTV
$507M
| $5.14K | ﹤0.01% |
+510
| New | +$6.13K |
|
612
Inhibrx
INBX
$1.24B
| $4.68K | ﹤0.01% |
+304
| New | +$4.63K |
|
613
Lexeo Therapeutics
LXEO
$342M
| $4.57K | ﹤0.01% |
+694
| New | +$5.47K |
|
|
IGMS
614
DELISTED
IGM Biosciences
IGMS
| $4.38K | ﹤0.01% |
+716
| New | +$8.51K |
|
615
MacroGenics
MGNX
$240M
| $4.28K | ﹤0.01% |
+1,318
| New | +$4.75K |
|
616
Alector
ALEC
$180M
| $4.05K | ﹤0.01% |
+2,145
| New | +$8.07K |
|
|
CMPS
617
Compass Pathways
CMPS
$1.56B
| $4.04K | ﹤0.01% |
+1,068
| New | +$5.42K |
|
618
Fate Therapeutics
FATE
$293M
| $3.94K | ﹤0.01% |
+2,391
| New | +$6.03K |
|
619
Acrivon Therapeutics
ACRV
$65.1M
| $3.94K | ﹤0.01% |
+654
| New | +$4.75K |
|
620
Tevogen Bio Holdings
TVGN
$28.4M
| $3.79K | ﹤0.01% |
+74
| New | +$4.82K |
|
|
INZY
621
DELISTED
Inozyme Pharma
INZY
| $3.74K | ﹤0.01% |
+1,349
| New | +$5.13K |
|
|
SCPH
622
DELISTED
scPharmaceuticals
SCPH
| $3.72K | ﹤0.01% |
+1,051
| New | +$4.03K |
|
|
MRSN
623
DELISTED
Mersana Therapeutics
MRSN
| $3.71K | ﹤0.01% |
+104
| New | +$5.38K |
|
624
Nkarta
NKTX
$154M
| $3.69K | ﹤0.01% |
+1,482
| New | +$4.58K |
|
625
Kyverna Therapeutics
KYTX
$455M
| $3.39K | ﹤0.01% |
+906
| New | +$4.34K |
|
Similar funds
CM
BP
AAM
CAG
RCG
AL
CGPCS
EAM
GF Fund Management's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for GF Fund Management, which disclosed 637 positions worth $4.62B. Its ten largest holdings account for 48% of the portfolio.
Its largest position is NVIDIA: 2,904,119 shares worth $390M.
By sector, the portfolio is most concentrated in Technology at 45% of assets, followed by Consumer Discretionary and Communication Services.
- GF Fund Management's largest Q4 2024 buy was NVIDIA: 2,904,119 shares worth $390M.
- GF Fund Management's ten largest holdings make up 48% of its $4.62B portfolio in Q4 2024.
- GF Fund Management disclosed 637 positions in Q4 2024, its first 13F filing on record.
Based on GF Fund Management's 13F filing for Q4 2024, filed 19 Feb 2025.